130 related articles for article (PubMed ID: 22192652)
1. Paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors.
Schultheis B; Neumann H; Roy R; Heuer V; Kummer G; Strumberg D
Int J Clin Pharmacol Ther; 2012 Jan; 50(1):72-3. PubMed ID: 22192652
[No Abstract] [Full Text] [Related]
2. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
Azad NS; Posadas EM; Kwitkowski VE; Steinberg SM; Jain L; Annunziata CM; Minasian L; Sarosy G; Kotz HL; Premkumar A; Cao L; McNally D; Chow C; Chen HX; Wright JJ; Figg WD; Kohn EC
J Clin Oncol; 2008 Aug; 26(22):3709-14. PubMed ID: 18669456
[TBL] [Abstract][Full Text] [Related]
3. Challenges and pitfalls of combining targeted agents in phase I studies.
Cannistra SA
J Clin Oncol; 2008 Aug; 26(22):3665-7. PubMed ID: 18669449
[No Abstract] [Full Text] [Related]
4. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.
Falchook GS; Wheler JJ; Naing A; Piha-Paul SA; Fu S; Tsimberidou AM; Hong DS; Janku F; Zinner R; Jiang Y; Huang M; Lin Q; Parkhurst K; Kurzrock R
Invest New Drugs; 2015 Feb; 33(1):215-24. PubMed ID: 25363205
[TBL] [Abstract][Full Text] [Related]
5. Targeting angiogenesis in bladder cancer.
Elfiky AA; Rosenberg JE
Curr Oncol Rep; 2009 May; 11(3):244-9. PubMed ID: 19336017
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib in locally advanced or metastatic breast cancer.
Gradishar WJ
Expert Opin Investig Drugs; 2012 Aug; 21(8):1177-91. PubMed ID: 22616580
[TBL] [Abstract][Full Text] [Related]
7. Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Barbastefano J; Garcia JA; Elson P; Wood LS; Lane BR; Dreicer R; Campbell SC; Rini BI
BJU Int; 2010 Nov; 106(9):1266-9. PubMed ID: 20346042
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity.
Lee JM; Sarosy GA; Annunziata CM; Azad N; Minasian L; Kotz H; Squires J; Houston N; Kohn EC
Br J Cancer; 2010 Feb; 102(3):495-9. PubMed ID: 20051952
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.
Flaherty KT; Schiller J; Schuchter LM; Liu G; Tuveson DA; Redlinger M; Lathia C; Xia C; Petrenciuc O; Hingorani SR; Jacobetz MA; Van Belle PA; Elder D; Brose MS; Weber BL; Albertini MR; O'Dwyer PJ
Clin Cancer Res; 2008 Aug; 14(15):4836-42. PubMed ID: 18676756
[TBL] [Abstract][Full Text] [Related]
10. VEGF inhibition and metastasis: possible implications for antiangiogenic therapy.
English BC; Price DK; Figg WD
Cancer Biol Ther; 2009 Jul; 8(13):1214-25. PubMed ID: 19483467
[No Abstract] [Full Text] [Related]
11. Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.
Subbiah V; Slopis J; Hong DS; Ketonen LM; Hamilton J; McCutcheon IE; Kurzrock R
J Clin Oncol; 2012 Feb; 30(5):e64-8. PubMed ID: 22203760
[No Abstract] [Full Text] [Related]
12. A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109.
Mina LA; Yu M; Johnson C; Burkhardt C; Miller KD; Zon R
Invest New Drugs; 2013 Oct; 31(5):1307-10. PubMed ID: 23812905
[TBL] [Abstract][Full Text] [Related]
13. [Oncology 2008].
Stemmler HJ; Heinemann V
Dtsch Med Wochenschr; 2008 Jun; 133(25-26):1395-9. PubMed ID: 18521794
[No Abstract] [Full Text] [Related]
14. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.
Azad NS; Aragon-Ching JB; Dahut WL; Gutierrez M; Figg WD; Jain L; Steinberg SM; Turner ML; Kohn EC; Kong HH
Clin Cancer Res; 2009 Feb; 15(4):1411-6. PubMed ID: 19228742
[TBL] [Abstract][Full Text] [Related]
15. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.
Jain L; Sissung TM; Danesi R; Kohn EC; Dahut WL; Kummar S; Venzon D; Liewehr D; English BC; Baum CE; Yarchoan R; Giaccone G; Venitz J; Price DK; Figg WD
J Exp Clin Cancer Res; 2010 Jul; 29(1):95. PubMed ID: 20630084
[TBL] [Abstract][Full Text] [Related]
16. Anti-angiogenic therapies in metastatic breast cancer-an unfulfilled dream.
Buzdar AU
Lancet Oncol; 2011 Apr; 12(4):316-8. PubMed ID: 21429798
[No Abstract] [Full Text] [Related]
17. A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.
Desar IM; Timmer-Bonte JN; Burger DM; van der Graaf WT; van Herpen CM
Br J Cancer; 2010 Nov; 103(11):1637-43. PubMed ID: 21045832
[TBL] [Abstract][Full Text] [Related]
18. Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.
Rosen LS; Puzanov I; Friberg G; Chan E; Hwang YC; Deng H; Gilbert J; Mahalingam D; McCaffery I; Michael SA; Mita AC; Mita MM; Mulay M; Shubhakar P; Zhu M; Sarantopoulos J
Clin Cancer Res; 2012 Jun; 18(12):3414-27. PubMed ID: 22510349
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies.
Hong DS; Sebti SM; Newman RA; Blaskovich MA; Ye L; Gagel RF; Moulder S; Wheler JJ; Naing A; Tannir NM; Ng CS; Sherman SI; El Naggar AK; Khan R; Trent J; Wright JJ; Kurzrock R
Clin Cancer Res; 2009 Nov; 15(22):7061-8. PubMed ID: 19903778
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: stable radiographic disease with decreased AFP.
Marsh AM; Lo L; Cohen RA; Feusner JH
Pediatr Blood Cancer; 2012 Nov; 59(5):939-40. PubMed ID: 22492703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]